KIM, JONG WONKR,김종원,PARK, JONG HOKR,박종호,WOO, YOUNG MINKR,우영민,PARK, IN HOKR,박인호,PARK, KYUNG SUNKR,박경선
申请号：
KR1020160149766
公开号：
KR1020170055435A
申请日:
2016.11.10
申请国别(地区):
KR
年份:
2017
代理人:
摘要：
The present invention relates to: a pharmaceutical composition for preventing or treating malignant tumors which includes a formulation for inhibiting the expression of HMGCLL1 IS3 a pharmaceutical composition for preventing or treating malignant tumors exhibiting resistance to a tyrosine kinase inhibitor a method for providing information for determining drug resistance of an individual with a malignant tumor by using a level of expression of HMGCLL1 IS3 a composition and a kit for diagnosing drug resistance used in the same method a method for providing information for determining the possibility of disease occurrence from a malignant tumor by using the level of expression of HMGCLL1 IS3 a method for screening a malignant tumor treatment agent by using the level of expression of HMGCLL1 IS3 a method for providing information for predicting the prognosis of a malignant tumor by using the level of expression of HMGCLL1 IS3 a composition for predicting prognosis of a malignant tumor containing a formulation capable of measuring the level of expression of HMGCLL1 IS3 and a kit thereof a method for providing information for determining drug resistance of an individual with a malignant tumor by using SNP a composition for determining drug resistance and a kit use for the same method a method for providing information for determining the possibility of disease occurrence from a malignant tumor by using SNP and a method for providing information for predicting the prognosis of a malignant tumor by using SNP and a composition for predicting the prognosis of a malignant tumor and a kit used for the same method. When the methods of the present invention are used, drug resistance of a patient who suffers from chronic myelogenous leukemia and a malignant tumor can be effectively predicted or diagnosed, and, furthermore, the methods can be used for effective drug treatment and research and development of effective drugs.COPYRIGHT KIPO 2017본 발명은 HMGCLL1 IS3의 발현을 억제하는 제제를 포함하는 악성
